Phaseline

Companies › iBio

iBio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IBIO-600–Phase 1Overweight , ObesityMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07487376IBIO-600Phase 1Overweight , ObesityMetabolic and endocrineMay 2027

From the company's SEC filings

Cash and short-term investments of $88m on 2026-06-30; operating cash outflow about $23m a year; runway about 45 months at that burn, to Apr 2030

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.